In Study 208, eribulin plus trastuzumab as first-line treatment for patients with HER2+ locally advanced BC or MBC demonstrated anti-tumor activity comparable to those reported for other chemotherapy combinations evaluated in this setting. This evidence concerns the gene ERBB2 and neoplasm.